Editorial policy
What we are, and what we are not
PeptideClear is an editorial and educational comparison service. Our content rests on published, peer-reviewed research and named UK regulatory sources (NICE, MHRA, NHS England, the BNF), cited so you can read the primary source yourself. We do not operate a medical board, we do not employ in-house clinicians, and we do not provide medical advice. Our editorial standards are overseen by a single named editor, Oliver Mackman, a director of the operating company Best Business Loans Ltd, who is responsible for sourcing, fact-checking, and sign-off against the rules below. He is not a doctor, and nothing on this site should be read as a substitute for advice from a qualified prescriber. Where a page touches a clinical decision, we cite the evidence and point you to a UK-registered clinician or pharmacy who can give personal advice.
Sources we lead with
- · NICE technology appraisals (TA1026 for tirzepatide; relevant guidelines for related medications)
- · NHS England commissioning guidance and ICB statements
- · MHRA enforcement notices, drug-safety bulletins, and Yellow Card data
- · Patient Information Leaflets (PILs) from Eli Lilly (Mounjaro) and Novo Nordisk (Wegovy, Ozempic)
- · British National Formulary (BNF) for prescribing reference
- · Peer-reviewed clinical trial publications (SURMOUNT, STEP, SELECT)
- · The Pharmaceutical Journal, Health Foundation, BHF, Diabetes UK
Sources we use carefully
- · UK private clinic and pharmacy materials (we cite for pricing and policy, not clinical claims)
- · International sources (US FDA, European EMA) where they pre-date UK guidance
- · Peer review with caveats
Sources we do not use
- · Reddit, Mumsnet, and other unverified user forums for clinical claims
- · Brand blogs as the primary source for clinical claims
- · Influencer or anecdotal content
- · US bodybuilding-forum dosing protocols
- · Compounded or grey-import GLP-1 sources
No personal medical advice
PeptideClear does not publish dose-specific scenarios, individual symptom-triage runbooks, or content that assumes the role of a clinician. Editorial framing is comparison, encyclopedia, and commentary. Where readers need clinical decisions (eligibility, dose changes, side-effect management, switching), the page directs to a UK clinic or pharmacy partner whose prescriber takes that role.
ASA / CAP code awareness
PeptideClear publishes editorial in line with the Advertising Standards Authority and the CAP code, particularly the rules governing health claims and the promotion of Prescription Only Medicines (POM). We do not name POM weight-loss medications in comparison-advertising contexts. We do not show before/after imagery. We do not target individual symptoms with branded medication references. While PeptideClear is not a regulated healthcare provider, UK advertising and consumer-protection rules (including the CAP Code) still apply to our commercial communications, and we hold ourselves to those standards.
MHRA awareness
The Medicines and Healthcare products Regulatory Agency regulates UK medicines and medical devices. PeptideClear is not a manufacturer, importer, or distributor of medicines, and we are not regulated by the MHRA. We monitor MHRA enforcement notices, drug-safety bulletins, and Yellow Card data and update affected editorial pages when MHRA guidance changes. We do not publish content that promotes compounded or grey-import medicines, including grey-route GLP-1.
No before/after imagery
We do not publish before/after weight-loss photos. The Advertising Standards Authority (ASA) treats them as misleading on POM advertising for GLP-1 medication. We agree.
No specific medication recommendations
We compare licensed routes (NHS, private clinic, online pharmacy). We summarise typical clinical practice. We do not recommend a specific medication, dose, or product to a specific person. Your prescriber does that, after a consultation.
Refresh cadence
Category and product comparison pages are refreshed when retailers, clinics, or regulatory guidance materially change. NICE, MHRA, NHS, and ASA notices trigger an immediate review of any affected page.
Corrections
Errors are corrected within 5 working days of being notified. Material corrections add a dated correction note to the page footer. Email [email protected].